CrossMark

Ferroptosis Regulation by Nutrient Signalling

Yingao Qi[1], Xiaoli Zhang[1], Zhihui Wu[1], Min Tian[1], Fang Chen[1,2], Wutai Guan[1,2]* and Shihai Zhang[1,2,3]* (iD)

[1]*Guangdong Province Key Laboratory of Animal Nutrition Control, College of Animal Science, South China Agricultural University, Guangzhou, 510642, China*
[2]*College of Animal Science and National Engineering Research Center for Breeding Swine Industry, South China Agricultural University, Guangzhou 510642, China*
[3]*Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, United States*

Abstract

Tremendous progress has been made in the field of ferroptosis since this regulated cell death process was first named in 2012. Ferroptosis is initiated upon redox imbalance and driven by excessive phospholipid peroxidation. Levels of multiple intracellular nutrients (iron, selenium, vitamin E and coenzyme Q_{10}) are intimately related to the cellular antioxidant system and participate in the regulation of ferroptosis. Dietary intake of monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA) regulates ferroptosis by directly modifying the fatty acid composition in cell membranes. In addition, amino acids and glucose (energy stress) manipulate the ferroptosis pathway through the nutrient-sensitive kinases mechanistic target of rapamycin complex 1 (mTORC1) and AMP-activated protein kinase (AMPK). Understanding the molecular interaction between nutrient signals and ferroptosis sensors might help in the identification of the roles of ferroptosis in normal physiology and in the development of novel pharmacological targets for the treatment of ferroptosis-related diseases.

Key words: Nutrient sensing: Se: Fe: AMPK: mTORC1: Ferroptosis

(Received 17 March 2021; revised 19 June 2021; accepted 30 June 2021; accepted manuscript published online 8 July 2021)

1. Introduction

Cell death is a predominant process in normal physiological development and the maintenance of homeostasis, and the dysregulation of cell death leads to various diseases, including cancer. Programmed cell death is characterised by necroptosis, apoptosis, autophagy and ferroptosis. The process of necroptosis is identified by swollen organelles and ruptured cell membranes. The main characteristics of apoptosis is cell shrinkage with chromatin condensation and DNA fragmentation. Intriguingly, the hallmarks of ferroptosis are condensed mitochondria, increased bilayer membrane density and a reduction in the number of mitochondrial cristae[1,2]. Ferroptosis, a form of iron-dependent cell death, was first named in 2012. It is caused by the depletion of glutathione (GSH) and the inactivation of the phospholipid peroxidase glutathione peroxidase 4 (GPX4)[1,3]. GPX4 is the only major antioxidant enzyme known to convert toxic lipid hydroperoxides (L-OOH) into non-toxic lipid alcohols (L-OH)[3]. Thus, the predominant characteristic of ferroptosis is the accumulation of oxidative phospholipids in the cell membrane, which could trigger cell death through unclear mechanism[4]. Ferroptosis has attracted considerable interest from basic and clinical researchers since it has been implicated in the occurrence and development of multiple diseases.

Cellular biological functions are largely regulated by extracellular and intracellular nutrients and their metabolite concentrations. A rapid and efficient response to nutrient levels is crucial for maintaining cellular homeostasis. Recently, substantial progress has been made in the field of ferroptosis and nutrient sensing. In this review, we mainly focus on the potential cross talk between ferroptosis and nutrient signalling factors.

2. The general pathway of ferroptosis

As the hallmark of ferroptosis, lipid peroxidation is triggered by non-enzymatic and enzymatic processes[5]. The non-enzymatic process is mainly catalysed by cellular free iron and oxygen and is known as the Fenton reaction (Figs. 1 and 2). Bis-allylic

---

Abbreviations: AA, arachidonic acid; ACS, acyl-CoA synthetase; ACSL 3/4, acyl-CoA synthetase long-chain 3 and 4; ACSL, acyl-CoA synthetase long-chain family member; AdA, adrenic acid; AMPK, AMP-activated protein kinase; FA, fatty acid; FSP1, ferroptosis suppressor protein 1; GPX4, glutathione peroxidase 4; GSH, glutathione; IRP1 and IRP2, iron-regulatory proteins 1 and 2; ISC, increases iron-sulphur cluster; L-OH, lipid alcohols; L-OOH, lipid hydroperoxides; LOX, lipoxygenase; MDA, malondialdehyde; mTORC1, mechanistic target of rapamycin complex 1; MUFA, monounsaturated fatty acid; PL•, phospholipid radicals; PLO•, pLOOH reacts with cellular ferrous iron to generate additional alkoxyl radicals; PLOO•, phospholipid peroxyl radical; PLOOH, PLOO• reacts with a PLH molecule to yield a molecule of hydroperoxide; PUFA, polyunsaturated fatty acid; ROS, reactive oxygen species; SCD1, stearoyl-coenzyme A desaturase-1; SFA, saturated fatty acid; SREBP1, sterol regulatory element-binding protein 1; SREBP1c, sterol regulatory element-binding protein 1c; TF, transferrin; TfR1, transferrin receptor 1; THN, tetrahydronaphthyridinol; TSC, tuberous sclerosis complex.

* **Correspondence:** Wutai Guan, email: wtguan@scau.edu.cn; Shihai Zhang, Email: zhangshihai@scau.edu.cn

Fig. 1. General view of ferroptosis. Ferroptosis is characterised by iron-dependent phospholipid peroxidation. It is mainly regulated by selenium-dependent and CoQ_{10}-dependent pathways. The selenium-dependent pathway is primarily dependent on the enzymatic activity of glutathione peroxidase 4 (GPX4), which is a unique selenoprotein that functions as a phospholipid peroxidase. Cellular cystine transportation has an intimate relationship with the selenium-dependent pathway. Briefly, cystine is transported by amino acid transporter system x_c^- and further oxidised into cysteine by thioredoxin reductase 1 (TXNRD1). Then, cysteine, glutamate and glycine are used to synthesise glutathione (GSH) by γ-glutamylcysteine synthetase (γ-GCS) and glutathione synthetase (GSS). As a cofactor of GPX4, GSH functions in conjunction with GPX4 to reduce L-OOH into L-OH. In the CoQ_{10}-dependent pathway, the suppressor protein 1 (FSP1)–ubiquinone system is critical for lipid peroxidation. FSP1 reduces ubiquinone to ubiquinol, which further decreases lipid radicals to prevent lipid oxidation. Ubiquinone is derived from dietary CoQ_{10} intake or synthesis through the mevalonate pathway. FSP1, ferroptosis sensitising protein 1; GSH, glutathione; GSR, glutathione reductase; GSSG, glutathione disulfide; PL-PUFA, polyunsaturated fatty acid- containing phospholipid; Tf, transferrin; TfR1, transferrin receptor 1.

hydrogen atoms (the weakest C-H bond) in polyunsaturated fatty acyl moieties are vulnerable to oxidation by oxygen species and preliminarily form phospholipid radicals (PL$^•$). After the initiation of lipid oxidation, PL$^•$ is converted into a phospholipid peroxyl radical (PLOO$^•$), releasing one molecule of oxygen. Subsequently, PLOO$^•$ reacts with a PLH molecule to yield a molecule of hydroperoxide (PLOOH) and PL$^{•(4)}$. As a form of

reactive oxygen species (ROS), PLOOH reacts with cellular ferrous iron to generate additional alkoxyl radicals (PLO$^•$) and PLOO$^•$. The reactions of lipid peroxidation lead to the accumulation of lipid-based oxidative secondary products such as 4-hydroxynonenal and malondialdehyde (MDA). This propagation process of lipid peroxidation is terminated when PLOOH is cleared in a timely manner by GPX4. The enzymatic process is

Fig. 2. Ferroptosis and phospholipid peroxidation. Polyunsaturated fatty acids contain bis-allylic hydrogen atoms, which are prone to removal, leading to the formation of phospholipid radicals (PL•). PL• reacts with O_2 to form PLOO• and is subsequently converted into PLOOH by lipoxygenase (LOX) and/or cytochrome P450 oxidoreductase (POR). Then, the iron-dependent Fenton reaction yields PLO• and PL•, which leads to the induction of PLOOH production. This lipid propagation is terminated when PLOO• is reduced by glutathione peroxidase 4 (GPX4).

also required to trigger ferroptosis (Fig. 2). Lipoxygenases (LOX) target PUFA located in lipid bilayers and regulate lipid peroxidation[6]. Inhibition of LOX makes cells more resistant to ferroptosis[7]. Cytochrome P450 oxidoreductase (POR) is the other critical regulator of ferroptosis; it induces lipid peroxidation by directly transferring hydrogen from PUFA or by indirectly converting Fe^{3+} into Fe^{2+} [8,9].

Cells have a protection program to safeguard them from ferroptosis. The canonical pathway to prevent ferroptosis in cells is mainly dependent on system x_c^- and GPX4 (Fig. 2). Mechanistically, system x_c^- regulates the cellular concentration of cystine, which could be converted into cysteine and further act as a critical substrate for GSH synthesis. GSH is a cofactor of GPX4, which reduces toxic PLOOH to corresponding non-toxic PLOHs. Inhibition of either system x_c^- or GPX4 induces ferroptosis. The system x_c^-–GSH–GPX4 axis is regarded as the most classical and is the best-studied pathway in the regulation of ferroptosis. Recently, studies identified a novel ubiquinone-dependent pathway in which FSP1 functions as an oxidoreductase to reduce ubiquinone to ubiquinol, which prevents lipid peroxidation[10,11].

3. Ferroptosis and iron

Iron has been known as a critical component for haemoglobin synthesis since 1932[12]. The role of iron in haemoglobin formation and oxygen transport has attracted the attention of nutritionists for many years. Insufficient iron intake has a direct connection to anaemia in many developing countries[13]. Recently, the accumulation of iron has been found to be closely related to ferroptosis. Iron is proposed to enhance lipid

peroxidation through the Fenton reaction or activation of enzymes such as LOX[14]. Mechanistically, iron reacts with PLOOH to generate the free radicals PLO• and PLOO•, which propagate peroxidation chain reactions[4].

Feeding animals an iron-enriched diet increases cellular iron loading (Fig. 3)[15]. Iron is absorbed in the upper intestine in the form of ferrous iron (Fe^{2+}), which is then quickly oxidised into a ferric ion (Fe^{3+}). Once exported from enterocytes, Fe^{3+} binds with transferrin (TF) and circulates in the blood circulatory system. This complex is recognised and imported by the transferrin receptor (TFRC) located in the cell membrane. Once taken up, the iron bound to TF is reduced from Fe^{3+} to Fe^{2+} by the STEAP3 metalloreductase in the endosome and is then transferred to the cytosol via solute carrier family 11 member 2 (SLC11A2). The enrichment of iron further sensitises cells to ferroptosis.

Iron storage and export are both critical processes that regulate intracellular iron levels (Fig. 3). Cellular free iron is stored by ferritins, which are composed of ferritin light chain (FTL) and ferritin heavy chain 1 (FTH1). Knocking down *Ftl* and *Fth1* increases the concentration of free iron, sensitising cells to ferroptosis triggered by GPX4 inhibition[16]. Similarly, overexpression of mitochondrial ferritin inhibits erastin-induced ferroptosis[17]. In addition to ferritin, multiple mitochondrial proteins (such as NFS1 cysteine desulphurase, CDGSH iron sulphur domain 1 and CDGSH iron sulphur domain 2) also regulate cellular iron concentrations by manipulating iron–sulphur cluster biogenesis[18–21]. Iron chelators (such as deferoxamine, deferasirox, deferiprone, ciclopirox and dexrazoxane) mimic the effects of ferritin and are widely used to treat iron overload diseases[22]. The other way to relieve iron overloading is through the regulation of iron export. Solute carrier family 40 member 1 (SLC40A1), which is also known as ferroportin, is the only known transporter of iron exportation. Siramesine is a sigma-2 receptor ligand, which is a lysosomotropic agent that can be used to treat depression[23], while lapatinib is originally identified as a dual tyrosine kinase inhibitor of ErbB1 and ErbB2 tyrosine kinase receptors[24]. The combination of siramesine and lapatinib has been reported to synergically regulate ferroptosis through iron regulatory proteins[25]. Overexpression of *SLC40A1* inhibits siramesine- and lapatinib-induced ferroptosis, whereas knockdown of *SLC40A1* promotes ferroptosis[25]. Consistently, prominin 2 (PROM2), a member of the prominin family of pentaspan membrane glycoproteins, regulates exosome-dependent iron exportation and desensitises cells to ferroptosis[16]. Some regulators participate in the modulation of cellular iron homeostasis. Iron-regulatory proteins 1 and 2 (IRP1 and IRP2) regulate the genes involved in iron uptake, export, storage and utilisation[26,27].

4. Ferroptosis and selenium

Selenium was discovered approximately 200 years ago by Swedish scientists. This element was originally regarded as a toxin in animals because livestock fed selenium-enriched plants suffered hair loss and a necrotic hoof malady[28]. With the gradual understanding of selenium, scientists have found that

Fig. 3. Ferroptosis and dietary nutrients (CoQ10, selenium, vitamin E and iron). Ferroptosis is an iron-dependent form of cell death. Thus, regulation of cellular iron concentration is critical to ferroptosis. Dietary iron includes haem iron and non-haem iron. Haem iron is directly transported into enterocytes through haem transporters (HT). Dietary ferric iron (Fe^{3+}) is reduced into ferritin iron (Fe^{2+}) by the ferric reductase enzyme cytochrome b (CYTB) and then transported into cells via divalent metal transporter 1 (DMT1). Subsequently, Fe^{2+} is exported by FPN1 and oxidised into Fe^{3+} by hephaestin (HP). Finally, Fe^{3+} is combined with transferrin (TF) and transported to targeted organs, which are recognised by the transferrin receptor (TFRC) in the cell membrane. Selenium is classified into organic selenium and inorganic selenium, both of which are absorbed in the small intestine. SeO_3^{2-} is passively absorbed by the gut, while SeO_4^{2-} seems to be transported by a sodium-mediated carrier. Organic forms of selenium are not recognised and are transported as minerals. For instance, selenomethionine (SeMet) and selenocysteine (SeCys) are transported in the form of amino acids. More than 50 % of selenium is converted into selenoprotein P (SELENOP) and transported to the targeted organs through blood. Low-density lipoprotein receptor-related protein 2 and 8 (LRP2/LRP8) are critical for receptor-dependent selenium uptake in different tissues. Cellular selenium is subsequently synthesised into GPX4 and protects cells from ferroptosis. Vitamin E and CoQ_{10} are both regarded as fat-soluble vitamins. Dietary vitamin E and CoQ_{10} are incorporated into micelles and absorbed by the small intestine. In enterocytes, vitamin E and CoQ_{10} are attached to chylomicrons and then transported to target organs through the lymph and blood circulation systems. CoQ_{10} (ubiquinone) is largely transformed into ubiquinol in lymph. In blood vessels, CoQ_{10} is attached to low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL), while vitamin E is attached to high-density lipoprotein (HDL). Mechanistically, ubiquinol directly prevents lipid peroxidation, whereas vitamin E regulates ferroptosis mainly by competing with lipoxygenases (LOX) for PUFA substrate-binding sites. FSP1, ferroptosis sensitising protein 1; FTH, ferritin heavy chain; FTL, ferritin light chain; FPN, fragipain; GPX4, glutathione peroxidase 4; HMG-CoA, β-Hydroxy β-methylglutaryl-CoA; ISCU, iron–sulphur cluster assembly enzyme; NCOA4, nuclear receptor coactivator 4; NFS1, nitrogen fixation 1 homologue; PL-PUFA, polyunsaturated fatty acid- containing phospholipid; POR, cytochrome P450 oxidoreductase; SLC40A1, solute carrier family 40 member 1; SLC11A2, solute carrier family 11, member 2.

Fig. 4. Ferroptosis and the mTORC1 signalling pathway. mTORC1 inhibits ferroptosis through three independent pathways. On the one hand, mTORC1 increases the expression of GPX4 and the abundance of GSH (through the up-regulation of amino acid transport system x_c^-). On the other hand, mTORC1 increases MUFA abundance in the plasma membrane through the SREBP1c/SCD1 pathway. Furthermore, mTORC1 might directly inhibit an increase the intracellular iron concentration through the ISCU/IRP/TfR1 signalling pathway. ACSL 3/4, acyl-CoA synthetase long-chain 3 and 4; γ-GCS, γ-glutamylcysteine synthetase; GPX4, glutathione peroxidase 4; GSH, glutathione; GSR, glutathione reductase; GSS, glutathione synthetase; GSSG, glutathione disulfide; IRP1/IRP2, iron regulatory protein 1 and 2; ISCU, iron–sulphur cluster assembly enzyme; LOX, lipoxygenases; LPCAT3, lysophospholipid *O*-acyltransferase 3; mTORC1, mechanistic target of rapamycin complex 1; PL-MUFA, monounsaturated fatty acids-containing phospholipid; PL-PUFA, polyunsaturated fatty acid-containing phospholipid; SCD1, stearoyl-CoA desaturase-1; SREBP1c, sterol regulatory element binding protein-1c; Tf, transferrin; TfR1, transferrin receptor 1; TXNRD1, thioredoxin reductase 1.

selenium is toxic at high levels[29] but essential at low levels[29]. Insufficient selenium induces various diseases, such as cancer, inflammation, immune disorders and nervous system diseases.

Selenium is a critical component of selenoproteins. Briefly, selenide (HSe⁻) is converted into selenophosphate ($H_2SePO_3^-$), which is incorporated into P-Ser-tRNA[Ser]Sec and used for selenoprotein synthesis[30]. Knockout of the Sec-specific tRNA gene *Trsp* (*nuclear encoded tRNA selenocysteine 2*) leads to lethality in mice during embryonic development[31]. To date, approximately twenty-five selenoproteins have been identified in humans[32,33]. Among these selenoproteins, GPX4 is the only antioxidant enzyme protecting cells from lipid peroxidation and ferroptosis. Similar to *Trsp* deficiency, knocking out *GPX4* in mice is lethal during the early embryonic period. Importantly, selenium utilisation by GPX4 is critical to inhibit ferroptosis[34]. The replacement of the catalytically active selenium to a cysteine in GPX4 makes cells highly sensitive to peroxide-induced ferroptosis[34]. The evidence obtained from this mutation indicates that selenolate-based catalysis of GPX4 is critical to prevent ferroptosis in cells.

Increasing selenium intake is an efficient way to increase the cell selenium concentration and protect cells from ferroptosis (Fig. 3). Dietary selenium is usually taken up as selenoproteins. Selenomethionine (SeMet, organic form) is absorbed most rapidly by all the intestinal segment, while selenate and selenite (inorganic form) can only be efficiently absorbed by the ileum[35]. Selenium salts are required to be converted into selenoamino acids before being absorbed by the intestine[36]. Thus, for dietary sources of selenoproteins, organic forms of selenium are absorbed more efficiently than inorganic forms. Selenoproteins can then be transported into the liver for selenoprotein P (SELENOP) synthesis[32]. Subsequently, SELENOP is delivered to target organs, which are recognised by low-density lipoprotein receptor-related protein 2 and 8 (LRP2 and LRP8)[37,38].

Ingestion of selenocysteine-containing peptides activates homeostatic transcription to inhibit ferroptosis and alleviate haemorrhagic or ischaemic stroke[39]. Notably, ingested selenium not only acts as a component in GPX4 synthesis but also drives the transcription of GPX4 through coordinated

Fig. 5. Ferroptosis and the AMPK signalling pathway. Inconsistent and contradictory results have been obtained in studies of AMPK and ferroptosis. (a) A group of scientists found that AMPK prevents ferroptosis by decreasing PUFA levels and increasing MUFA levels through the inhibition of ACC function. (b) Another group of scientists promotes an alternative view, suggesting that AMPK promotes ferroptosis with an increase in PUFA levels and a decrease in MUFA levels through activation of **ACSL4** and inactivation of the SREBP1c/SCD1 pathway. In addition, AMPK also inhibits the activity of amino acid transport system x_c^- via BECN1, which further triggers the initiation of ferroptosis. ACC, Acetyl-CoA carboxylase; ACSL 3/4, acyl-CoA synthetase long-chain 3 and 4; AMPK, 5'AMP- activated protein kinase; BECN1, beclin-1; GPX4, glutathione peroxidase 4; GSH, glutathione; LOXs, lipoxygenases; LPCAT3, lysophospholipid *O*-acyltransferase 3; PL-MUFA, monounsaturated fatty acids-containing phospholipid; PL-PUFA, polyunsaturated fatty acid-containing phospholipid; SCD1, stearoyl-CoA desaturase-1; SREBP1c, sterol regulatory element binding protein-1c.

activation of the transcription factors TFAP2c and Sp1 in neurons[39]. Interestingly, selenium deficiency drives adaptive transcription to attenuate ferroptotic insults, but this adaptation appears to be insufficient to protect cells from undergoing ferroptosis[39]. When dietary selenium is limited, selenium is preferentially enriched in the brain and testes, which indicates the predominant function of selenium-dependent enzymes in these organs[40]. This selective selenium distribution might partially explain why Parkinson's disease, Alzheimer's disease, dementia, seizures, coordination and cognitive decline are commonly identified in selenium-deficient individuals[41]. Together, nutritional supplementation with selenium is an efficient way to protect the cell from ferroptosis and its related metabolic diseases through the regulation of GPX4 in selenium-deficient individuals.

5. Ferroptosis and CoQ_{10}

Coenzyme Q_{10} (CoQ_{10}, also known as ubiquinone), a vitamin-like substance, is a lipid-soluble antioxidant used for the treatment of cardiovascular disease. CoQ_{10} maintains the mitochondrial membrane potential, promotes ATP synthesis and inhibits ROS generation. CoQ_{10} protects neuronal cells from oxidative stress and prevents related neurodegenerative diseases, including Parkinson's and Alzheimer's diseases[42,43].

Recently, CoQ_{10} has been reported to prevent the production of lipid peroxides. In addition to the canonical GSH-based GPX4

pathway, the non-mitochondrial CoQ_{10} antioxidant system acts in parallel to protect the cell from ferroptosis[11]. Ferroptosis suppressor protein 1 (FSP1) has been identified by two individual groups as a crucial ferroptosis-resistance factor[10,11]. In the plasma membrane, FSP1 functions as an oxidoreductase to reduce ubiquinone to ubiquinol and prevents lipid peroxidation. In addition, CoQ_{10} increases the phosphorylation of AMPK[44–46], which might be the other pathway that prevents ferroptosis. However, since the biological effects of AMPK signalling on ferroptosis are still unclear (additional details are discussed in the AMPK and ferroptosis sections), more research is warranted to determine whether CoQ_{10} is connected to ferroptosis through AMPK.

To date, no direct *in vivo* or *in vitro* evidence has indicated that administration of CoQ_{10} can rescue cells from ferroptosis. However, over many decades, the pharmaceutical use of CoQ_{10} has been demonstrated to restore respiratory chain activities and prevent oxidative stress. Dietary supplementation with CoQ_{10} prevents the initiation of lipid peroxidation[47,48], which is consistent with the results observed *in vitro*[49]. Similar to CoQ_{10}, the CoQ_{10} analogue idebenone also halts cellular lipid peroxidation[50]. In addition to dietary supplementation, CoQ_{10} is also synthesised through the mevalonate pathway. It has been reported that an inhibitor of HMG-CoA reductase (cerivastatin) or a scavenger of CoQ_{10} (compound FIN56) sensitises cells to ferroptosis[50]. Similarly, 4-chlorobenzoate inhibits CoQ_{10} production and triggers ferroptosis[11]. Thus, dietary

supplementation with CoQ$_{10}$ or an increase in CoQ$_{10}$ *de novo* synthesis might efficiently protect cells from ferroptosis.

6. Vitamin E and ferroptosis

Discovered approximately 100 years ago, vitamin E is one of most predominant inhibitors of ferroptosis[51]. Dietary vitamin E comprises eight homologues: α-, β-, γ- and δ-tocopherols and α-, β-, γ- and δ-tocotrienols. All of these isoforms are found to break the autoxidation chain reaction, especially α-tocopherol, which has the highest antioxidant activity[52,53]. Thus, clinial symptoms of vitamin E deficiency are similar to those of selenium deficiency. LOX-mediated lipid peroxidation has been implicated as a central event in ferroptosis. Tocotrienols and tocopherols regulate ferroptosis mainly through their competition with LOX (through a corking mechanism) for PUFA-substrate binding sites[54]. Tocotrienols are more effective than tocopherols in protecting cells from ferroptosis, as they are more effective LOX inhibitors[54]. Mechanistically, vitamin E inhibits LOX by reducing the non-haem iron in the enzyme (converts Fe^{3+} to Fe^{2+}).

Dietary supplementation with the lipophilic antioxidant vitamin E is an effective way to prevent ferroptosis and its related diseases. In an *in vivo* study, *Gpx4*-knockout mice fed a vitamin-E-deficient diet exhibited increased lipid peroxidation and hippocampal neurodegeneration[55]. Similarly, mice with endothelial cell knockout of *Gpx4* appear normal when fed a vitamin-E-sufficient diet but abnormal when fed a vitamin-E-insufficient diet[56]. Dietary supplementation with vitamin E restores the dysfunction of T cells induced by *Gpx4* deficiency[57]. In addition, severe embryo lipid peroxidation is observed when vitamin E is absent. Dietary supplementation with vitamin E during gestation prevents disruption in mouse embryonic fibroblasts, cortical neurons and even fetal lethality caused by GPX4 knockout[58,59]. Recently, α-tocopherol hydroquinone, an endogenous metabolite of vitamin E, was implicated as a more powerful inhibitor of ferroptosis than vitamin E[60].

To improve the biological function of vitamin E as ferroptosis inhibitors, scientists have attempted to develop better analogues of vitamin E. Tetrahydronaphthyridinols (THN) constitute a specific group of aza-phenols, which are considered the most promising synthetic compounds to inhibit ferroptosis[61]. The speed at which THN react with peroxyl radicals is almost 30-fold faster than that of α-tocopherol[62]. THN with alkyl chains ranging from twelve to fifteen carbons are more effective in protecting cells from ferroptosis than the classical ferroptosis inhibitors Fer-1 and Lip-1[63]. This evidence indicates that THN can efficiently inhibit ferroptosis.

7. Fatty acids and ferroptosis

Fatty acids (FA) are lipids that not only act as an energy sources and constitute portions of cellular membranes but also play multiple physiological roles. FA can be classified into saturated fatty acids (SFA), MUFA and PUFA based on the degree of hydrocarbon chain saturation. PUFA are predominant components in cellular, mitochondrial and retinal membranes. Cells (such as

neurons) with higher levels of PUFA are more sensitive to ferroptosis[64].

By using quantitative redox lipidomics, a study made clear that ferroptosis occurs in cells with high levels of plasma membrane phosphatidylethanolamines (PE), which are a class of specific phospholipids with two fatty acid chains – arachidonic acid (AA) and adrenic acid (AdA)[54]. Fatty acid elongation by very-long-chain fatty acid protein 5 (ELOVL5) and fatty acid desaturase 1 (FADS1) is required to maintain the intracellular levels of AA and AdA[65]. Blockage of AA or AdA esterification into PE efficiently prevents ferroptosis in cells. FA must be activated by acyl-CoA synthetase (ACS) before they can be incorporated into triacylglycerol (TAG)[66]. Among the five isoforms of acyl-CoA synthetase long-chain family members (ACSL), ACSL4 is specific for the activation of AA and AdA[67]. Intriguingly, ACSL4 seems to serve as a double-edged sword in terms of cell survival. On the one hand, ACSL4 decreases fatty acid-induced lipotoxicity[68]. On the other hand, ACSL4 drives esterification of AA and AdA into PE, which triggers ferroptosis[54]. Excess AA increases Fenton reaction-induced oxidative stress with the up-regulation of anti-inflammatory lipoxinA4 (LXA4) and down-regulation of prostaglandin E2 (PGE2) (LXA4 and PGE2 are proposed to promote and inhibit cell growth, respectively), which further induce cell death[68]. Thus, the effects of PUFA (AA and AdA) to promote cell survival or induce ferroptosis may be dose dependent[66].

Administration of cells with PUFA is an efficient way to promote ferroptosis. PUFA, especially AA, can induce inflammatory bowel disease (IBD) by triggering ferroptosis in *Gpx4*-deficient mice[69]. Dietary ingestion of the PUFA dihomo-γ-linolenic acid (DGLA; 20:3 n-6) induces ferroptosis in the nematode *Caenorhabditis elegans* and human cells[70]. These experiments propose that the enrichment of PUFA in the plasma membrane makes cells more susceptible to ferroptosis.

In contrast to PUFA, the administration of MUFA causes cells to enter a ferroptosis-insensitive state. Exogenous MUFA decrease lipid ROS accumulation and inhibit ferroptosis in an acyl-CoA synthetase long-chain family member 3 (ACSL3)-dependent manner[71]. Mechanistically, MUFA are converted into MUFA-PL by ACSL3, and they displace PUFA in the plasma membrane and hinder lipid ROS accumulation[71]. Clinically, increased serum MUFA prevent ferroptosis induced by neurodegeneration or kidney failure[72]. Overloading intracellular SFA triggers a specified apoptosis process called lipotoxicity[73]. Intriguingly, MUFA also protect cells from apoptotic lipotoxicity caused by SFA. Thus, modification of dietary MUFA levels can be an efficient way to regulate ferroptosis and lipotoxicity.

In addition to replacing PUFA with MUFA in the plasma membrane, increasing ether lipid abundance is an alternative way to protect cells from ferroptosis. Endogenous ether lipids are regarded as oxidative 'sinks' that protect PUFA chains from oxidation[74,75]. Infants with inherited ether lipid synthesis enzyme deficiency present with severe growth and mental disorders[76]. The synthesis of ether lipids protects *C. elegans* and human cancer cells from undergoing ferroptosis[70]. Future

studies need to clarify the potential methods to manipulate the synthesis of ether lipids.

8. mTOR signalling and ferroptosis

mTORC1 is a master regulator of protein synthesis, which is triggered by multiple stimuli, such as growth factors, energy levels and amino acids[77–79]. Amino acids regulate mTORC1 lysosomal localisation and subsequently activate mTORC1 through Rag GTPase-dependent and Rag GTPase-independent pathways[80–82]. The small G-protein Ras homologue enriched in the brain (Rheb) contains a CAAX (C = Cys, A = aliphatic, X = terminal amino acid) box, which facilitates its localisation to lysosomes[83,84]. Rheb directly interacts with mTORC1 and triggers conformational changes in mTOR, triggering its activation[85]. In contrast to amino acids, growth factors activate mTORC1 by stimulating the dissociation of the tuberous sclerosis complex (TSC) from the lysosome and Rheb[83]. TSC is a negative regulator of mTORC1, and its mutation constitutively activates mTORC1[86–88]. mTORC1 is composed of three components: the catalytic component mTOR, the regulatory-associated protein of mTOR (Raptor) and mammalian lethal with Sec13 protein 8 (mLST8, also known as $G_{\beta L}$). Raptor recognises mTORC1 substrates, and mLST8 acts as a positive regulator of mTOR activity. Activation of mTORC1 regulates mRNA translation and protein transcription through the phosphorylation of eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) and S6 kinase (S6K1), which are the two key downstream substrates of the mTORC1 complex.

Recently, activation of mTORC1 was reported to prevent lipid peroxide accumulation and suppress ferroptosis[89]. This effect was partially due to mTORC1 signalling participating in the regulation of lipid metabolism. As a transcriptional target of sterol regulatory element-binding protein 1 (SREBP1), stearoyl-coenzyme A desaturase-1 (SCD1) is critical for the conversion of SFA into MUFA. Synthesised MUFA displace PUFA in the plasma membrane and inhibit the accumulation of lipid ROS[71]. Knocking out either *SREBP1* or *SCD1* impaired the effects of mTORC1 on ferroptosis[89]. Exogenous MUFA palmitoleic acid (16:1, PO) or oleate acid (18:1, OA) supplementation also restores ferroptosis resistance when mTORC1 signalling is depressed. This evidence indicates that mTORC1 signalling protects cells from ferroptosis through the SREBP1/SCD1-mediated synthesis of MUFA (Fig. 4).

Another connection between mTORC1 signalling and ferroptosis is GPX4 (Fig. 4). Han *et al.*[90] also observed that inhibition of mTORC1 was accompanied by a decrease in GPX4 level. In addition, some preliminary evidence suggests that mTOR signalling might be required to maintain the expression of SLC7A11[91]. SLC7A11 is critical for cystine transportation, which is required for GSH synthesis and GPX4 activity.

In addition, mTORC1 is proposed to regulate ferroptosis directly through the modulation of the iron transport system (Fig. 4). Some evidence indicates that the activation of mTORC1 decreases the cellular iron concentration. mTORC1 phosphorylates iron–sulphur cluster assembly enzyme (ISCU) at serine 14 and increases iron–sulphur cluster (ISC)

assembly[92,93]. Stabilisation of ISCU further inhibits IRP1/IRP2 function, promoting ferroportin 1 (Fpn1, a protein that mainly mediates iron export) and decreasing cellular iron concentration[94]. Notably, however, the effect of mTORC1 on cellular iron concentration is inconsistent. Bayeva *et al.*[94] reported that activation of mTORC1 negatively regulates the expression of tristetraprolin, which binds to Transferrin receptor 1 (TfR1) mRNA to enhance its degradation. TfR1 is a protein that mainly mediates iron import. Thus, activation of mTORC1 is proposed to increase cellular iron concentration. Future experiments are needed to clarify the effect of mTOR on iron transport.

In clinical research, mTORC1 plays a vital role in iron metabolism in cardiomyocytes. Approximately 80 % of mTOR-treated orthotopic heart transplant patients have functional iron deficiency[95]. In cardiomyocytes, activation of mTOR protects against ferroptosis partially by decreasing ROS production[96]. An in-depth understanding of the cross talk between mTOR signalling and ferroptosis will lead to a novel therapy for patients with myocardial infarction.

9. Energy sensing and ferroptosis

Energy homeostasis is important to sustain the biological function of cells. AMPK acts as the predominant energy sensor in eukaryotic cells[97]. The adenylation system (ATP + ADP + AMP) has been measured to estimate cellular energy levels since 1976[98,99]. Increased ADP and AMP indicate a decrease in cellular energy status. AMPK is a heterotrimer that contains an α catalytic subunit, β regulatory subunit and γ regulatory subunit[100]. AMPK subunits include multiple isoforms, such as α1, α2, β1, β2, γ1, γ2 and γ3[101]. The classical pathway to AMPK activation (phosphorylation at Thr172) is dependent on increased levels of ADP and AMP[102].

Recently, AMPK has been shown to be a critical regulator of ferroptosis (Fig. 5). Cells with AMPK activation are more resistant to ferroptosis, while those with AMPK inactivation are more sensitive to ferroptosis[103–105]. This AMPK effect is due to the energy stress-impaired biosynthesis of PUFA, especially arachidonic acid (C20:4) and adrenic acid (C22:4), which are required for ferroptosis[54]. Mechanistically, AMPK regulates ferroptosis partially through phosphorylation of ACC, which inhibits PUFA-containing lipid biosynthesis and makes cells more resistant to ferroptosis[103,105]. Inhibition (treatment with 5-(tetradecyloxy)-2-furoic acid) or site mutation (mutation of ACC1 Ser79 to ACC1 Ala79; mutation of ACC2 Ser212 to ACC Ala212) of ACC mimics the protective role of AMPK activation in ferroptosis[103]. This evidence proposes a protective mechanism that protects cells from organ injury induced by energy failure. For instance, energy stress was found to protect against renal ischaemia–reperfusion injury[103].

Notably, there is a fierce debate regarding the role of AMPK in the regulation of ferroptosis (Fig. 5). Cells under energy stress commonly show increased ROS production, which indicates the promotion of ferroptosis[106]. Song *et al.*[107] observed that activation of AMPK is required for BECN1-induced ferroptosis, a finding in opposition to the results shown by Lee *et al.*[103]. BECN1 is a crucial regulator of macroautophagy/autophagy[108].

Mechanistically, activation of AMPK phosphorylates BECN1 at Ser90/93/96 and promotes BECN1–SLC7A11 complex formation; this complex blocks system x_c^--regulated homeostasis in GSH and induces ferroptosis[107,109]. In addition, Zhao *et al.*[110] found that inactivation of AMPK promotes SREBP1/SCD1 expression, which inhibits ferroptosis with the production of MUFAs. However, it is worth noting that activation of SREBP1, a critical transcriptional regulator of lipogenesis, is proposed to promote the production of both MUFA and PUFA, but not specific MUFA. Thus, more studies are required to confirm this finding. Notably, AMPK is the upstream and negative regulator of mTORC1[111]. As activation of mTORC1 protects the cell from ferroptosis, it is reasonable to hypothesise that the activation of AMPK promotes ferroptosis.

Mitochondria are predominant organelles that participate in energy production and the regulation of ferroptosis. It is worth noting that the potential mechanism of mitochondria-triggered ferroptosis is also controversial. Some evidence indicates that the mitochondrial TCA cycle and electron transfer chain increase lipid peroxide accumulation and promote ferroptosis induced by cysteine deprivation[112,113]. However, one study reported that functional mitochondrial electron transfer chain is not required in erastin-induced cell death[1]. In addition, mitochondria have many other functions independent of the electron transfer chain that could contribute to ferroptosis, such as tumor suppressor protein p53[114] and enzymes involved in mitochondrial respiration[114,115]. Interestingly, mitochondria were involved only in ferroptosis caused by cysteine deprivation but not by GPX4 inhibition (induced by RSL3)[112]. This result might be due to inhibited GPX4 quickly enhancing the accumulation of lipid ROS in other pathways that remain active, a supposition that requires further study. Clinically, MitoTEMPO (a superoxide scavenger targeted to the mitochondria) decreases lipid peroxidation and protects the heart from ischemia/reperfusion (IR)-induced damage[116]. Understanding the physiological functions of mitochondria and AMPK in the regulation of ferroptosis will help in identifying novel pharmacological targets for ferroptosis-related diseases.

10. Conclusions and perspectives

Tremendous progress has been made in the field of ferroptosis in recent years. Multiple nutrients have been reported to regulate redox homeostasis and lipid peroxidation. To date, nutrients participating in ferroptosis regulation are classified into three categories: (1) selenium, iron, vitamin E and CoQ$_{10}$, which mediate the production of PLOOH generated in cells; (2) exogenous fatty acids that manipulate the fatty acid profiles of cellular membranes (mainly in monogastric animals); and (3) amino acids and energy stress, which trigger the activation of mTORC1 and AMPK signalling pathways related to ferroptosis. However, our understanding of ferroptosis and the cross talk of its factors with nutrient signalling factors is still limited but is expected to explode in the coming years. Critical issues in this field that must be addressed are listed below.

First, ferroptosis is not only involved in diverse diseases but might also be critical to regulate normal physiology. Under physiological conditions, iron and ROS are involved in the regulation of cellular biological functions. Once a threshold is crossed, iron overload and oxidative damage can cause ferroptotic cell death. MDA, a critical marker of lipid peroxidation, is generally increased in animals under heat and oxidative stress[117,118]. In contrast to classical ferroptosis, the accumulation of MDA under heat and oxidative stress is usually insufficient to induce a notable increase in the cell death rate. Thus, the possibility that sublethal ferroptosis can reprogram cell metabolism and biological functions in different cells and/or organs needs to be studied in the future. In addition, the thresholds for inducing sublethal ferroptosis-related damage are unknown. Nutritional strategies may be an efficient way to manipulate sublethal ferroptosis-related disorders.

Second, current findings on the cross talk between ferroptosis and nutrient sensing factors are not consistent, especially results related to ferroptosis and AMPK. To date, an intense debate rages regarding the biological function of AMPK in cancer cells[119,120]. The signalling model of AMPK and ferroptosis might be more complicated than the current model. For instance, AMPK regulates not only lipid metabolism through the phosphorylation of ACC1 and ACC2 but also sterol regulatory element-binding protein 1c (SREBP1c) and PPAR γ coactivator 1α (PGC1α)[121,122]. The expression and effects of SREBP1c and PGC1α vary by cell type. Therefore, the effects of AMPK-regulated ferroptosis could be cell type- or tissue-dependent.

Third, iron is not the only ion to trigger the Fenton reaction, which raises the question, why is ferroptosis more sensitive to liable iron concentrations? Recently, some studies have indicated that other ions also participate in the regulation of ferroptosis. For instance, under specific conditions, copper regulates the initiation of ferroptosis[123]. Endoplasmic reticulum zinc homeostasis is closely related to ferroptosis[124]. Thus, future studies are required to determine whether current findings are missing critical information regarding other ions with respect to ferroptosis.

In addition to the unclear connections between nutrient sensing and ferroptosis, precise biological markers for ferroptosis need to be clarified in the future. Although the expression of some genes (for instance, prostaglandin-endoperoxide synthase 2 (PTGS2/COX2), ChaC glutathione-specific γ-glutamylcyclotransferase 1 (CHAC1/BOTCH), nuclear factor erythroid 2-like 2 (NFE2L2/NRF2)) is related to the process of ferroptosis, these genes are not uniquely involved in ferroptosis[125]. Furthermore, potential connections among ferroptosis, apoptosis and autophagy need to be explored. It is difficult to separate ferroptosis from other types of cell death. Nutrient signalling regulates not only ferroptosis but also apoptosis[126,127] and autophagy[128,129]. Future studies need to answer the following questions: What is the precise relationship among different types of cell death? Does nutrient signalling individually regulate different types of cell death, or does it regulate cell death processes in combination?

In summary, an in-depth understanding of ferroptosis and nutrient signalling might lead to a new approach for the therapeutic intervention of ferroptosis-related diseases, such as cancer, neurodegeneration and inflammation. Further study should focus on ferroptosis in both non-pathological and the normal physiology contexts.

Financial Support

Authors' contributions

Yingao Qi and Shihai Zhang initiated the idea, the scope and the outline of this review paper. Yingao Qi, Xiaoli zhang, Min Tian, Shihai Zhang, Zhihui Wu, Jinghui Heng and Fang Chen studied and analysed all of the publications cited in this paper and were involved in the manuscript preparation. Shihai Zhang and Wutai Guan conducted the final editing and proofreading. All authors read and approved the final manuscript.

Conflicts of interest

The authors declare that they have no competing interests.

References

1. Dixon SJ, Lemberg KM, Lamprecht MR *et al.* (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. *Cell* **149**, 1060–1072.
2. Yagoda N, von Rechenberg M, Zaganjor E *et al.* (2007) RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. *Nature* **447**, 864–868.
3. Yang WS, SriRamaratnam R, Welsch ME *et al.* (2014) Regulation of ferroptotic cancer cell death by GPX4. *Cell* **156**, 317–331.
4. Conrad M, Pratt DA (2019) The chemical basis of ferroptosis. *Nat Chem Biol* **15**, 1137–1147.
5. Gaschler MM, Stockwell BR (2017) Lipid peroxidation in cell death. *Biochem Biophys Res Commun* **482**, 419–425.
6. Kuhn H, Banthiya S, Van Leyen K (2015) Mammalian lipoxygenases and their biological relevance. *Biochim Biophys Acta Mol Cell Biol Lipids* **1851**, 308–330.
7. Li Y, Maher P, Schubert D (1997) A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. *Neuron* **19**, 453–463.
8. Zou Y, Li H, Graham ET *et al.* (2020) Cytochrome P450 oxidoreductase contributes to phospholipid peroxidation in ferroptosis. *Nat Chem Biol* **16**, 302–309.
9. Ghosh MK, Mukhopadhyay M, Chatterjee IB (1997) NADPH-initiated cytochrome P450-dependent free iron-independent microsomal lipid peroxidation: specific prevention by ascorbic acid. *Mol Cell Biochem* **166**, 35–44.
10. Doll S, Freitas FP, Shah R *et al.* (2019) FSP1 is a glutathione-independent ferroptosis suppressor. *Nature* **575**, 693–698.
11. Bersuker K, Hendricks JM, Li Z *et al.* (2019) The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. *Nature* **575**, 688–692.
12. Abbaspour N, Hurrell R, Kelishadi R (2014) Review on iron and its importance for human health. *J Res Med Sci* **19**, 164.
13. Dary O, Hurrell R (2006) Guidelines on food fortification with micronutrients. *World Health Organization, Food and Agricultural Organization of the United Nations: Geneva, Switzerland*, 1–376.
14. Yang WS, Kim KJ, Gaschler MM *et al.* (2016) Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. *Proc Natl Acad Sci* **113**, E4966–E4975.
15. Yu Y, Jiang L, Wang H *et al.* (2020) Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis. *Blood J Am Soc Hematol* **136**, 726–739.
16. Brown CW, Amante JJ, Chhoy P *et al.* (2019) Prominin2 drives ferroptosis resistance by stimulating iron export. *Dev Cell* **51**, 575–586. e574.
17. Wang Y-Q, Chang S-Y, Wu Q *et al.* (2016) The protective role of mitochondrial ferritin on erastin-induced ferroptosis. *Front Aging Neurosci* **8**, 308.
18. Alvarez SW, Sviderskiy VO, Terzi EM *et al.* (2017) NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis. *Nature* **551**, 639–643.
19. Du J, Wang T, Li Y *et al.* (2019) DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin. *Free Radic Biol Med* **131**, 356–369.
20. Yuan H, Li X, Zhang X *et al.* (2016) CISD1 inhibits ferroptosis by protection against mitochondrial lipid peroxidation. *Biochem Biophys Res Commun* **478**, 838–844.
21. Kim EH, Shin D, Lee J *et al.* (2018) CISD2 inhibition overcomes resistance to sulfasalazine-induced ferroptotic cell death in head and neck cancer. *Cancer Lett* **432**, 180–190.
22. Chen X, Yu C, Kang R *et al.* (2020) Iron metabolism in ferroptosis. *Front Cell Develop Biol* **8**.
23. Heading C (2001) Siramesine H Lundbeck. *Curr Opin Invest Drugs (London, England: 2000)* **2**, 266–270.
24. Xia W, Gerard CM, Liu L *et al.* (2005) Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. *Oncogene* **24**, 6213–6221.
25. Ma S, Henson E, Chen Y *et al.* (2016) Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. *Cell Death Dis* **7**, e2307–e2307.
26. Zhang D-L, Ghosh MC, Rouault TA (2014) The physiological functions of iron regulatory proteins in iron homeostasis – an update. *Front Pharmacol* **5**, 124.
27. Volz K (2008) The functional duality of iron regulatory protein 1. *Curr Opin Struct Biol* **18**, 106–111.
28. Franke KW (1934) A new toxicant occurring naturally in certain samples of plant foodstuffs. 1. Results obtained in preliminary feeding trials. *J Nutr* **8**, 597–608.
29. Hatfield DL, Tsuji PA, Carlson BA *et al.* (2014) Selenium and selenocysteine: roles in cancer, health, and development. *Trends Biochem Sci* **39**, 112–120.
30. Conrad M, Proneth B (2020) Selenium: tracing another essential element of ferroptotic cell death. *Cell Chem Biol* **27**, 409–419.
31. Bosl MR, Takaku K, Oshima M *et al.* (1997) Early embryonic lethality caused by targeted disruption of the mouse selenocysteine tRNA gene (Trsp). *Proc Natl Acad Sci U S A* **94**, 5531–5534.
32. Gladyshev VN, Arner ES, Berry MJ *et al.* (2016) Selenoprotein Gene Nomenclature. *J Biol Chem* **291**, 24036–24040.
33. Kryukov GV, Castellano S, Novoselov SV *et al.* (2003) Characterization of mammalian selenoproteomes. *Science (80-)* **300**, 1439–1443.
34. Ingold I, Berndt C, Schmitt S *et al.* (2018) Selenium utilization by GPX4 is required to prevent hydroperoxide-induced ferroptosis. *Cell* **172**, 409–422.e421.
35. Vendeland SC, Butler JA, Whanger PD (1992) Intestinal absorption of selenite, selenate, and selenomethionine in the rat. *J Nutr Biochem* **3**, 359–365.

36. Wolffram S, Ardüser F, Scharrer E (1985) In vivo intestinal absorption of selenate and selenite by rats. *J Nutr* **115**, 454–459.

37. Burk RF, Hill KE (2009) Selenoprotein P-expression, functions, and roles in mammals. *Biochim Biophys Acta* **1790**, 1441–1447.

38. Chiu-Ugalde J, Theilig F, Behrends T *et al.* (2010) Mutation of megalin leads to urinary loss of selenoprotein P and selenium deficiency in serum, liver, kidneys and brain. *Biochem J* **431**, 103–111.

39. Alim I, Caulfield JT, Chen Y *et al.* (2019) Selenium drives a transcriptional adaptive program to block ferroptosis and treat stroke. *Cell* **177**, 1262–1279 e1225.

40. Schomburg L, Schweizer U (2009) Hierarchical regulation of selenoprotein expression and sex-specific effects of selenium. *Biochim Biophys Acta* **1790**, 1453–1462.

41. Rayman MP (2012) Selenium and human health. *Lancet* **379**, 1256–1268.

42. McCarthy S, Somayajulu M, Sikorska M *et al.* (2004) Paraquat induces oxidative stress and neuronal cell death; neuroprotection by water-soluble Coenzyme Q10. *Toxicol Appl Pharmacol* **201**, 21–31.

43. Flint Beal M, Shults CW (2003) Effects of Coenzyme Q10 in Huntington's disease and early Parkinson's disease. *BioFactors* **18**, 153–161.

44. Xie T, Wang C, Jin Y *et al.* (2020) CoenzymeQ10-induced activation of AMPK-YAP-OPA1 pathway alleviates atherosclerosis by improving mitochondrial function, inhibiting oxidative stress and promoting energy metabolism. *Front Pharmacol* **11**, 1034.

45. Chen K, Chen X, Xue H *et al.* (2019) Coenzyme Q10 attenuates high-fat diet-induced non-alcoholic fatty liver disease through activation of the AMPK pathway. *Food Function* **10**, 814–823.

46. Lee SK, Lee JO, Kim JH *et al.* (2012) Coenzyme Q10 increases the fatty acid oxidation through AMPK-mediated PPARα induction in 3T3-L1 preadipocytes. *Cell Signal* **24**, 2329–2336.

47. Mohr D, Bowry VW, Stocker R (1992) Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. *Biochim Biophys Acta Lipids Lipid Metab* **1126**, 247–254.

48. Choy KJ, Deng Y-M, Hou JY *et al.* (2003) Coenzyme Q10 supplementation inhibits aortic lipid oxidation but fails to attenuate intimal thickening in balloon-injured New Zealand White rabbits. *Free Radic Biol Med* **35**, 300–309.

49. Ahmadvand H, Mabuchi H, Nohara A *et al.* (2013) Effects of coenzyme Q10 on LDL oxidation in vitro. *Acta Med Iran*, 12–18.

50. Shimada K, Skouta R, Kaplan A *et al.* (2016) Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. *Nat Chem Biol* **12**, 497–503.

51. Evans HM, Bishop KS (1922) On the existence of a hitherto unrecognized dietary factor essential for reproduction. *Science (80-)* **56**, 650–651.

52. Burton G, Ingold KU (1986) Vitamin E: application of the principles of physical organic chemistry to the exploration of its structure and function. *Acc Chem Res* **19**, 194–201.

53. Khanna S, Roy S, Ryu H *et al.* (2003) Molecular basis of vitamin E action: tocotrienol modulates 12-lipoxygenase, a key mediator of glutamate-induced neurodegeneration. *J Biol Chem* **278**, 43508–43515.

54. Kagan VE, Mao G, Qu F *et al.* (2017) Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. **13**, 81–90.

55. Hambright WS, Fonseca RS, Chen L *et al.* (2017) Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. *Redox Biol* **12**, 8–17.

56. Wortmann M, Schneider M, Pircher J *et al.* (2013) Combined deficiency in glutathione peroxidase 4 and vitamin E causes multiorgan thrombus formation and early death in mice. *Circ Res* **113**, 408–417.

57. Matsushita M, Freigang S, Schneider C *et al.* (2015) T cell lipid peroxidation induces ferroptosis and prevents immunity to infection. *J Exp Med* **212**, 555–568.

58. Carlson BA, Tobe R, Yefremova E *et al.* (2016) Glutathione peroxidase 4 and vitamin E cooperatively prevent hepatocellular degeneration. *Redox Biol* **9**, 22–31.

59. Seiler A, Schneider M, Forster H *et al.* (2008) Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-Mediated cell death. *Cell Metab* **8**, 237–248.

60. Hinman A, Holst CR, Latham JC *et al.* (2018) Vitamin E hydroquinone is an endogenous regulator of ferroptosis via redox control of 15-lipoxygenase. *PLoS One* **13**.

61. Valgimigli L, Pratt DA (2015) Maximizing the reactivity of phenolic and aminic radical-trapping antioxidants: just add nitrogen! *Acc Chem Res* **48**, 966–975.

62. Nam TG, Rector CL, Kim HY *et al.* (2007) Tetrahydro-1,8-naphthyridinol analogues of alpha-tocopherol as antioxidants in lipid membranes and low-density lipoproteins. *J Am Chem Soc* **129**, 10211–10219.

63. Zilka O, Shah R, Li B *et al.* (2017) On the mechanism of cytoprotection by ferrostatin-1 and liproxstatin-1 and the role of lipid peroxidation in ferroptotic cell death. *ACS Cent Sci* **3**, 232–243.

64. Doll S, Proneth B, Tyurina YY *et al.* (2017) ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. *Nat Chem Biol* **13**, 91–98.

65. Lee J-Y, Nam M, Son HY *et al.* (2020) Polyunsaturated fatty acid biosynthesis pathway determines ferroptosis sensitivity in gastric cancer. *Proc Natl Acad Sci* **117**, 32433–32442.

66. Tang Y, Zhou J, Hooi SC *et al.* (2018) Fatty acid activation in carcinogenesis and cancer development: Essential roles of long-chain acyl-CoA synthetases. *Oncol Lett* **16**, 1390–1396.

67. Doll S, Proneth B, Tyurina YY *et al.* (2017) ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. *Nat Chem Biol* **13**, 91–98.

68. Das UN (2019) Saturated fatty acids, MUFAs and PUFAs regulate ferroptosis. *Cell Chem Biol* **26**, 309–311.

69. Mayr L, Grabherr F, Schwärzler J *et al.* (2020) Dietary lipids fuel GPX4-restricted enteritis resembling Crohn's disease. *Nat Commun* **11**, 1–15.

70. Perez MA, Magtanong L, Dixon SJ *et al.* (2020) Dietary lipids induce ferroptosis in Caenorhabditiselegans and human cancer cells. *Dev Cell* **54**, 447–454. e444.

71. Magtanong L, Ko PJ, To M *et al.* (2019) Exogenous monounsaturated fatty acids promote a ferroptosis-resistant cell state. *Cell Chem Biol* **26**, 420–432 e429.

72. Stockwell BR, Friedmann Angeli JP, Bayir H *et al.* (2017) Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. *Cell* **171**, 273–285.

73. Garbarino J, Sturley SL (2009) Saturated with fat: new perspectives on lipotoxicity. *Curr Opin Clin Nutr Metab Care* **12**, 110–116.

74. Shi X, Tarazona P, Brock TJ *et al.* (2016) A Caenorhabditis elegans model for ether lipid biosynthesis and function. *J Lipid Res* **57**, 265–275.

75. Wallner S, Schmitz G (2011) Plasmalogens the neglected regulatory and scavenging lipid species. *Chem Phys Lipids* **164**, 573–589.

76. Wanders RJ, Waterham HR (2006) Peroxisomal disorders: the single peroxisomal enzyme deficiencies. *Biochim Biophys Acta Mol Cell Res* **1763**, 1707–1720.

77. Jewell JL, Russell RC, Guan K-L (2013) Amino acid signalling upstream of mTOR. *Nat Rev Mol Cell Biol* **14**, 133–139.

78. Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. *Nat Rev Mol Cell Biol* **12**, 21–35.

79. Gomes AP, Blenis J (2015) A nexus for cellular homeostasis: the interplay between metabolic and signal transduction pathways. *Curr Opin Biotechnol* **34**, 110–117.

80. Liu GY, Sabatini DM (2020) mTOR at the nexus of nutrition, growth, ageing and disease. *Nat Rev Mol Cell Biol*, 1–21.

81. Meng D, Yang Q, Wang H *et al.* (2020) Glutamine and asparagine activate mTORC1 independently of Rag GTPases. *J Biol Chem* **295**, 2890–2899.

82. Jewell JL, Kim YC, Russell RC *et al.* (2015) Differential regulation of mTORC1 by leucine and glutamine. *Science* **347**, 194–198.

83. Menon S, Dibble CC, Talbott G *et al.* (2014) Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. *Cell* **156**, 771–785.

84. Sancak Y, Bar-Peled L, Zoncu R *et al.* (2010) Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. *Cell* **141**, 290–303.

85. Yang H, Jiang X, Li B *et al.* (2017) Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40. *Nature* **552**, 368–373.

86. Carsillo T, Astrinidis A, Henske EP (2000) Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. *Proc Natl Acad Sci* **97**, 6085–6090.

87. Inoki K, Guan K-L (2009) Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment. *Hum Mol Genet* **18**, R94–R100.

88. Kwiatkowski DJ, Manning BD (2005) Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. *Hum Mol Genet* **14**, R251–R258.

89. Yi J, Zhu J, Wu J *et al.* (2020) Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis. *Proc Natl Acad Sci* **117**, 31189–31197.

90. Han D, Jiang L, Gu X *et al.* (2020) SIRT3 deficiency is resistant to autophagy-dependent ferroptosis by inhibiting the AMPK/mTOR pathway and promoting GPX4 levels. *J Cell Physiol* **235**, 8839–8851.

91. Zhang L, Liu W, Liu F *et al.* (2020) IMCA induces ferroptosis mediated by SLC7A11 through the AMPK/mTOR pathway in colorectal cancer. *Oxid Med Cell Longev* **2020**.

92. Guan P, Wang N (2014) Mammalian target of rapamycin coordinates iron metabolism with iron-sulfur cluster assembly enzyme and tristetraprolin. *Nutrition* **30**, 968–974.

93. La P, Yang G, Dennery PA (2013) Mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation stabilizes ISCU protein: implications for iron metabolism. *J Biol Chem* **288**, 12901–12909.

94. Bayeva M, Khechaduri A, Puig S *et al.* (2012) mTOR regulates cellular iron homeostasis through tristetraprolin. *Cell Metab* **16**, 645–657.

95. Przybylowski P, Malyszko J, Macdougall I *et al.* (2013) Iron metabolism, hepcidin, and anemia in orthotopic heart transplantation recipients treated with mammalian target of rapamycin. *Transplant Proc* **45**, 387–390.

96. Baba Y, Higa JK, Shimada BK *et al.* (2018) Protective effects of the mechanistic target of rapamycin against excess iron and ferroptosis in cardiomyocytes. *Am J Physiol Heart Circ Physiol* **314**, H659–H668.

97. Hardie DG (2007) AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. *Nat Rev Mol Cell Biol* **8**, 774–785.

98. Atkinson DE, Fall L (1967) Adenosine triphosphate conservation in biosynthetic regulation: Escherichia coli phosphoribosylpyrophosphate synthase. *J Biol Chem* **242**, 3241–3242.

99. Atkinson DE, Walton GM (1967) Adenosine triphosphate conservation in metabolic regulation: rat liver citrate cleavage enzyme. *J Biol Chem* **242**, 3239–3241.

100. Xiao B, Sanders MJ, Underwood E *et al.* (2011) Structure of mammalian AMPK and its regulation by ADP. *Nature* **472**, 230–233.

101. Hardie DG, Hawley SA, Scott JW (2006) AMP-activated protein kinase – development of the energy sensor concept. *J Physiol* **574**, 7–15.

102. Hawley SA, Boudeau J, Reid JL *et al.* (2003) Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade. *J Biol* **2**, 1–16.

103. Lee H, Zandkarimi F, Zhang Y (2020) Energy-stress-mediated AMPK activation inhibits ferroptosis. *Nat Cell Biol* **22**, 225–234.

104. Li C, Dong X, Du W *et al.* (2020) LKB1-AMPK axis negatively regulates ferroptosis by inhibiting fatty acid synthesis. *Signal Transduct Target Ther* **5**, 1–4.

105. Currais A, Huang L, Goldberg J *et al.* (2019) Elevating acetyl-CoA levels reduces aspects of brain aging. *eLife* **8**, e47866.

106. Hay N (2016) Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? *Nat Rev Cancer* **16**, 635.

107. Song X, Zhu S, Chen P *et al.* (2018) AMPK-mediated BECN1 phosphorylation promotes ferroptosis by directly blocking system Xc⁻ activity. *Curr Biol* **28**, 2388–2399.e2385.

108. Liang XH, Jackson S, Seaman M *et al.* (1999) Induction of autophagy and inhibition of tumorigenesis by beclin 1. *Nature* **402**, 672–676.

109. Zhong Y, Tian F, Ma H *et al.* (2020) FTY720 induces ferroptosis and autophagy via PP2A/AMPK pathway in multiple myeloma cells. *Life Sci* **260**, 118077.

110. Zhao Y, Li M, Yao X *et al.* (2020) HCAR1/MCT1 regulates tumor ferroptosis through the lactate-mediated AMPK-SCD1 activity and its therapeutic implications. *Cell Rep* **33**, 108487.

111. Xu J, Ji J, Yan X-H (2012) Cross-talk between AMPK and mTOR in regulating energy balance. *Crit Rev Food Sci Nutr* **52**, 373–381.

112. Gao M, Yi J, Zhu J *et al.* (2019) Role of mitochondria in ferroptosis. *Mol Cell* **73**, 354–363.e353.

113. Basit F, Van Oppen LM, Schöckel L *et al.* (2017) Mitochondrial complex I inhibition triggers a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis in melanoma cells. *Cell Death Dis* **8**, e2716–e2716.

114. Zhang W, Gai C, Ding D *et al.* (2018) Targeted p53 on small-molecules-induced ferroptosis in cancers. *Front Oncol* **8**, 507.

115. Venkatesh S, Li M, Saito T *et al.* (2019) Mitochondrial LonP1 protects cardiomyocytes from ischemia/reperfusion injury in vivo. *J Mol Cell Cardiol* **128**, 38–50.

116. Fang X, Wang H (2019) Ferroptosis as a target for protection against cardiomyopathy. *Proc Natl Acad Sci U S A* **116**, 2672–2680.

Nutrition Research Reviews

117. Gaweł S, Wardas M, Niedworok E et al. (2004) Malondialdehyde (MDA) as a lipid peroxidation marker. Wiadomosci lekarskie (Warsaw, Poland: 1960) 57, 453–455.

118. Gonzalez-Rivas PA, Chauhan SS, Ha M et al. (2020) Effects of heat stress on animal physiology, metabolism, and meat quality: a review. Meat Sci 162, 108025.

119. Ross FA, MacKintosh C, Hardie DG (2016) AMP-activated protein kinase: a cellular energy sensor that comes in 12 flavours. FEBS J 283, 2987–3001.

120. Hardie DG (2015) Molecular pathways: is AMPK a friend or a foe in cancer? Clin Cancer Res 21, 3836–3840.

121. Kohjima M, Higuchi N, Kato M et al. (2008) SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int J Mol Med 21, 507–511.

122. Li W, Wong CC, Zhang X et al. (2018) CAB39L elicited an anti-Warburg effect via a LKB1-AMPK-PGC1α axis to inhibit gastric tumorigenesis. Oncogene 37, 6383–6398.

123. Maher P (2018) Potentiation of glutathione loss and nerve cell death by the transition metals iron and copper: implications for age-related neurodegenerative diseases. Free Radic Biol Med 115, 92–104.

124. Chen P-H, Wu J, Xu Y et al. (2021) Zinc transporter ZIP7 is a novel determinant of ferroptosis. Cell Death Dis 12, 1–12.

125. Chen X, Comish PB, Tang D et al. (2021) Characteristics and biomarkers of ferroptosis. Front Cell Develop Biol 9, 30.

126. Pintus F, Floris G, Rufini A (2012) Nutrient availability links mitochondria, apoptosis, and obesity. Aging (Albany NY) 4, 734.

127. Molina AJ, Wikstrom JD, Stiles L et al. (2009) Mitochondrial networking protects β-cells from nutrient-induced apoptosis. Diabetes 58, 2303–2315.

128. Lee JM, Wagner M, Xiao R et al. (2014) Nutrient-sensing nuclear receptors coordinate autophagy. Nature 516, 112–115.

129. Russell RC, Yuan H-X, Guan K-L (2014) Autophagy regulation by nutrient signaling. Cell Res 24, 42–57.